Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Colorectal Neoplasms

  Free Subscription

Articles published in Int J Cancer

Retrieve available abstracts of 87 articles:
HTML format

Single Articles

    May 2023
  1. AHADOVA A, Witt J, Haupt S, Gallon R, et al
    Is HLA type a possible cancer risk modifier in Lynch syndrome?
    Int J Cancer. 2023;152:2024-2031.
    PubMed     Abstract available

    April 2023
  2. GRINSHPUN A, Kustanovich A, Neiman D, Lehmann-Werman R, et al
    A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer.
    Int J Cancer. 2023;152:1444-1451.
    PubMed     Abstract available

    March 2023
  3. VITHAYATHIL M, Smith S, Song M
    Epidemiology of overall and early-onset serrated polyps versus conventional adenomas in a colonoscopy screening cohort.
    Int J Cancer. 2023;152:1085-1094.
    PubMed     Abstract available

  4. SIEVANEN T, Korhonen TM, Jokela T, Ahtiainen M, et al
    Systemic circulating microRNA landscape in Lynch syndrome.
    Int J Cancer. 2023;152:932-944.
    PubMed     Abstract available

  5. HEISSER T, Cardoso R, Niedermaier T, Hoffmeister M, et al
    Making colonoscopy-based screening more efficient: A "gateopener" approach.
    Int J Cancer. 2023;152:952-961.
    PubMed     Abstract available

    February 2023
  6. YUAN S, Mason AM, Titova OE, Vithayathil M, et al
    Morning chronotype and digestive tract cancers: Mendelian randomization study.
    Int J Cancer. 2023;152:697-704.
    PubMed     Abstract available

  7. YAO J, Chen Y, Lin Z
    Exosomes: Mediators in Microenvironment of Colorectal Cancer.
    Int J Cancer. 2023 Feb 9. doi: 10.1002/ijc.34471.
    PubMed     Abstract available

  8. WANG K, Olen O, Emilsson L, Khalili H, et al
    Association of inflammatory bowel disease in first-degree relatives with risk of colorectal cancer: A nationwide case-control study in Sweden.
    Int J Cancer. 2023 Feb 9. doi: 10.1002/ijc.34470.
    PubMed     Abstract available

  9. WANG Q, Shen X, Chen G, Du J, et al
    How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: from mechanisms to translation.
    Int J Cancer. 2023 Feb 8. doi: 10.1002/ijc.34464.
    PubMed     Abstract available

  10. CHEN X, Heisser T, Cardoso R, Hoffmeister M, et al
    Overall and age-specific risk advancement periods of colorectal cancer for men versus women: implications for gender-sensitive screening offers?
    Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34455.
    PubMed     Abstract available

  11. LV T, Shen L, Xu X, Yao Y, et al
    Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Int J Cancer. 2023;152:524-535.
    PubMed     Abstract available

    January 2023
  12. MAO Z, Baker JR, Takeuchi M, Hyogo H, et al
    Pre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients.
    Int J Cancer. 2023 Jan 30. doi: 10.1002/ijc.34449.
    PubMed     Abstract available

  13. BALTUSSEN JC, de Glas NA, Liefers GJ, Slingerland M, et al
    Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: a population-based study.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34422.
    PubMed     Abstract available

  14. EEFSEN RL, Larsen JS, Klarskov LL, Altaf R, et al
    Therapy with pembrolizumab in treatment-naive patients with non-metastatic, mismatch repair deficient colorectal cancer.
    Int J Cancer. 2023 Jan 3. doi: 10.1002/ijc.34420.
    PubMed     Abstract available

    December 2022
  15. REN J, Zhang P, Li Z, Zhang X, et al
    Association of screening status, polygenic risk score, and environmental risk factors with colorectal cancer incidence and mortality risks.
    Int J Cancer. 2022 Dec 20. doi: 10.1002/ijc.34407.
    PubMed     Abstract available

  16. SHIMOMURA Y, Zha L, Komukai S, Narii N, et al
    Mediation effect of intestinal microbiota on the relationship between fiber intake and colorectal cancer.
    Int J Cancer. 2022 Dec 15. doi: 10.1002/ijc.34398.
    PubMed     Abstract available

    November 2022
  17. BREEKVELDT ECH, Toes-Zoutendijk E, van de Schootbrugge-Vandermeer HJ, de Jonge L, et al
    Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34373.
    PubMed     Abstract available

  18. SCHWARZ S, Hornschuch M, Pox C, Haug U, et al
    Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34375.
    PubMed     Abstract available

  19. RIBE SG, Botteri E, Loberg M, Randel KR, et al
    Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34351.
    PubMed     Abstract available

  20. VAN DER KRUIJSSEN DEW, van der Kuil AJS, Vink GR, Punt CJA, et al
    Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a population-based study and meta-analysis.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34347.
    PubMed     Abstract available

    October 2022
  21. VAN DER MEER R, Bakkers C, van Erning FN, Simkens LHJ, et al
    A propensity score matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34325.
    PubMed     Abstract available

  22. LI Z, Jia Y, Zhu H, Yuan H, et al
    Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
    Int J Cancer. 2022;151:1382-1393.
    PubMed     Abstract available

    September 2022
  23. BETGE J, Jackstadt R
    From organoids to bedside: advances in modeling, decoding and targeting of colorectal cancer.
    Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34297.
    PubMed     Abstract available

  24. GU Y, Duan B, Sha J, Zhang R, et al
    Serum IgG N-glycans Enable Early Detection and Early Relapse Prediction of Colorectal Cancer.
    Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34298.
    PubMed     Abstract available

  25. WATTS K, Wills C, Madi A, Palles C, et al
    Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Int J Cancer. 2022;151:957-966.
    PubMed     Abstract available

  26. SUN M, Bjorge T, Teleka S, Engeland A, et al
    Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study.
    Int J Cancer. 2022;151:859-868.
    PubMed     Abstract available

  27. MARTIN-MORALES L, Manzano S, Rodrigo-Faus M, Vicente-Barrueco A, et al
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34289.
    PubMed     Abstract available

  28. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available

  29. BEGUM M, Lewison G, Wang X, Dunne PD, et al
    Global Colorectal Cancer Research, 2007-21: Outputs and Funding.
    Int J Cancer. 2022 Sep 8. doi: 10.1002/ijc.34279.
    PubMed     Abstract available

    August 2022
  30. DESHMUKH AA, Damgacioglu H, Georges D, Sonawane K, et al
    Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis.
    Int J Cancer. 2022 Aug 28. doi: 10.1002/ijc.34269.
    PubMed     Abstract available

  31. LJUNGGREN M, Weibull CE, Palmer G, Osterlund E, et al
    Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34255.
    PubMed     Abstract available

  32. AKHOUNDOVA D, Hussung S, Sivakumar S, Topfer A, et al
    ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34257.
    PubMed     Abstract available

  33. YIN L, Li H, Shi L, Chen K, et al
    Research Advances in Nanomedicine Applied to the Systemic Treatment of Colorectal Cancer.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34256.
    PubMed     Abstract available

  34. VAN ROEKEL EH, Bours MJL, Breukink SO, Aquarius M, et al
    Longitudinal associations of plasma metabolites with persistent fatigue among colorectal cancer survivors up to 2 years after treatment.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34252.
    PubMed     Abstract available

  35. LUKIC M, Licaj I, Laaksonen MA, Weiderpass E, et al
    The burden of colon cancer attributable to modifiable factors-The Norwegian Women and Cancer Study.
    Int J Cancer. 2022 Aug 10. doi: 10.1002/ijc.34237.
    PubMed     Abstract available

  36. MARTINI G, Ciardiello D, Dallio M, Famiglietti V, et al
    Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Int J Cancer. 2022;151:473-480.
    PubMed     Abstract available

  37. HARLID S, Van Guelpen B, Qu C, Gylling B, et al
    Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.
    Int J Cancer. 2022;151:348-360.
    PubMed     Abstract available

    July 2022
  38. VAN BLARIGAN EL, Ma C, Ou FS, Bainter TM, et al
    Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34230.
    PubMed     Abstract available

  39. XU X, Duan X, Wang S, Zhang Y, et al
    Special issue "The advance of solid tumor research in China": Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signaling.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34227.
    PubMed     Abstract available

  40. DIAS CARVALHO P, Martins F, Mendonca S, Ribeiro A, et al
    Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis.
    Int J Cancer. 2022 Jul 23. doi: 10.1002/ijc.34225.
    PubMed     Abstract available

  41. LIU T, Zhang Q, Song C, Siyin ST, et al
    C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study.
    Int J Cancer. 2022;151:297-307.
    PubMed     Abstract available

  42. CLARKE MA, Deshmukh AA, Suk R, Roberts J, et al
    A Systematic Review and Meta-Analysis of Cytology and HPV-related Biomarkers for Anal Cancer Screening Among Different Risk Groups.
    Int J Cancer. 2022 Jul 6. doi: 10.1002/ijc.34199.
    PubMed     Abstract available

  43. ROELANDT P, Droogne W, Voros G, Van Aelst L, et al
    Are heart transplant recipients more at risk for anal squamous carcinoma than other solid organ transplant recipients?
    Int J Cancer. 2022;151:156-157.

  44. ACHILLI P, Magistro C, Abd El Aziz MA, Calini G, et al
    Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world.
    Int J Cancer. 2022;151:120-127.
    PubMed     Abstract available

  45. LI J, You L, Xu Z, Bai H, et al
    Healthy lifestyle and the risk of conventional adenomas and serrated polyps: Findings from a large colonoscopy screening population.
    Int J Cancer. 2022;151:67-76.
    PubMed     Abstract available

  46. SOLOMON A, Alteber Z, Bassan D, Sharbi-Yunger A, et al
    On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
    Int J Cancer. 2022;151:107-119.
    PubMed     Abstract available

    June 2022
  47. PING J, Yang Y, Wen W, Kweon SS, et al
    Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians.
    Int J Cancer. 2022 Jun 29. doi: 10.1002/ijc.34194.
    PubMed     Abstract available

  48. FATEMI N, Tierling S, Es HA, Varkiani M, et al
    DNA Methylation Biomarkers in Colorectal Cancer: Clinical Applications for Precision Medicine.
    Int J Cancer. 2022 Jun 22. doi: 10.1002/ijc.34186.
    PubMed     Abstract available

  49. WATANABE J, Maeda H, Nagasaka T, Yokota M, et al
    Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer - Exploratory sequential examination of acquired mutations in circulating cell-free DN
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34184.
    PubMed     Abstract available

  50. JIANG Z, Yang Z
    Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34175.

  51. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
    Reply to "Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage".
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34177.

  52. WANG L, Knudsen MD, Lo CH, Wang K, et al
    Adherence to a healthy lifestyle in relation to colorectal cancer incidence and all-cause mortality after endoscopic polypectomy: a prospective study in three U.S. cohorts.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34176.
    PubMed     Abstract available

  53. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
    Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
    Int J Cancer. 2022;150:1978-1986.
    PubMed     Abstract available

  54. TORREGROSA C, Pernot S, Vaflard P, Perret A, et al
    FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34166.
    PubMed     Abstract available

  55. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    PubMed     Abstract available

  56. RAIMONDI A, Randon G, Prisciandaro M, Pagani F, et al
    Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial.
    Int J Cancer. 2022 Jun 9. doi: 10.1002/ijc.34156.
    PubMed     Abstract available

  57. BAMBERG LV, Heigwer F, Wandmacher AM, Singh A, et al
    Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34155.
    PubMed     Abstract available

  58. VAN ROOIJEN KL, Derksen JWG, Verkooijen HM, Vink GR, et al
    Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34149.
    PubMed     Abstract available

  59. ELMAHDI R, Wennerstrom ECM, Andersson M, Wohlfahrt J, et al
    Shared Environment and Colorectal Cancer: A Nordic Pedigree Registry-based Cohort Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34148.
    PubMed     Abstract available

  60. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
    Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
    PubMed     Abstract available

  61. FABER MT, Frederiksen K, Palefsky JM, Kjaer SK, et al
    A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34143.
    PubMed     Abstract available

    May 2022
  62. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed     Abstract available

    April 2022
  63. VAN DIJK E, van Werkhoven E, Asher R, Mooi JK, et al
    Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer; a post-hoc analysis of the randomized phase III-trial AGITG-MAX.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34061.
    PubMed     Abstract available

  64. LI M, Gong J, Bao Y, Huang D, et al
    Special issue "The advance of solid tumor research in China": Prognosis prediction for stage II colorectal cancer by fusing CT radiomics and deep-learning features of primary lesions and peripheral lymph nodes.
    Int J Cancer. 2022 Apr 29. doi: 10.1002/ijc.34053.
    PubMed     Abstract available

  65. CHEN LJ, Nguyen TNM, Chang-Claude J, Hoffmeister M, et al
    Incorporation of functional status, frailty, comorbidities, and co-medication in prediction models for colorectal cancer survival.
    Int J Cancer. 2022 Apr 18. doi: 10.1002/ijc.34036.
    PubMed     Abstract available

  66. BOTTERI E, Hoff G, Randel KR, Holme O, et al
    Characteristics of non-participants in a randomized colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing.
    Int J Cancer. 2022 Apr 12. doi: 10.1002/ijc.34025.
    PubMed     Abstract available

    February 2022
  67. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
    Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation through IL-6-induced regulation of DNA damage in vitro.
    Int J Cancer. 2022 Feb 25. doi: 10.1002/ijc.33982.
    PubMed     Abstract available

  68. OH CR, Kim JE, Hong YS, Kim SY, et al
    Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33966.
    PubMed     Abstract available

  69. IERACI L, Eberg M, Forster K, Murray PM, et al
    Development of population-level colon cancer pathway concordance measures and association with survival.
    Int J Cancer. 2022 Feb 16. doi: 10.1002/ijc.33964.
    PubMed     Abstract available

  70. GEBHARD C, Mulet-Lazaro R, Glatz D, Schwarzfischer-Pfeilschifter L, et al
    Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype.
    Int J Cancer. 2022;150:617-625.
    PubMed     Abstract available

  71. MIAO Y, Xu Z, Feng W, Zheng M, et al
    Platelet infiltration predicts survival in postsurgical colorectal cancer patients.
    Int J Cancer. 2022;150:509-520.
    PubMed     Abstract available

    January 2022
  72. LUU XQ, Lee K, Jun JK, Suh M, et al
    Effect of colorectal cancer screening on long-term survival of colorectal cancer patients: Results of the Korea National Cancer Screening Program.
    Int J Cancer. 2022 Jan 31. doi: 10.1002/ijc.33953.
    PubMed     Abstract available

  73. AO T, Mochizuki S, Kajiwara Y, Yonemura K, et al
    Cancer-associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: potential role of ADAM9.
    Int J Cancer. 2022 Jan 26. doi: 10.1002/ijc.33947.
    PubMed     Abstract available

  74. ZHOU X, Wang L, Xiao J, Sun J, et al
    Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33945.
    PubMed     Abstract available

  75. JENNISKENS JCA, Offermans K, Simons CCJM, Samarska I, et al
    Energy balance-related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg-effect.
    Int J Cancer. 2022 Jan 22. doi: 10.1002/ijc.33941.
    PubMed     Abstract available

  76. TORTORA K, Margheri F, Luceri C, Mocali A, et al
    Colon fibroblasts from Pirc rats (F344/NTac-Apc(am1137) ) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis.
    Int J Cancer. 2022;150:362-373.
    PubMed     Abstract available

  77. KEMPF E, Priou S, Lame G, Daniel C, et al
    Impact of two waves of Sars-Cov2 outbreak on the number, clinical presentation, care trajectories and survival of patients newly referred for a colorectal cancer: A French multicentric cohort study from a large group of University hospitals.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33928.
    PubMed     Abstract available

  78. YU YC, Paragomi P, Wang R, Jin A, et al
    Composite Dietary Antioxidant Index and the Risk of Colorectal Cancer: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33925.
    PubMed     Abstract available

    December 2021
  79. VANGALA DB, Ladigan-Badura S, Engel C, Huneburg R, et al
    Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome.
    Int J Cancer. 2021;149:2052-2062.
    PubMed     Abstract available

  80. HUANG Y, Hua X, Labadie JD, Harrison TA, et al
    Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex- and lifestyle factors- specific associations.
    Int J Cancer. 2021 Dec 9. doi: 10.1002/ijc.33897.
    PubMed     Abstract available

  81. HEISSER T, Hoffmeister M, Brenner H
    Model based evaluation of long-term efficacy of existing and alternative colorectal cancer screening offers: A case study for Germany.
    Int J Cancer. 2021 Dec 8. doi: 10.1002/ijc.33894.
    PubMed     Abstract available

  82. LUU HN, Tran MT, Nguyen MV, Tuong TT, et al
    Association between body mass index and colorectal adenomas: Findings from a case-control study in Vietnam.
    Int J Cancer. 2021;149:1898-1909.
    PubMed     Abstract available

  83. NIEDERMAIER T, Heisser T, Gies A, Guo F, et al
    To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population.
    Int J Cancer. 2021;149:1877-1886.
    PubMed     Abstract available

    November 2021
  84. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    PubMed     Abstract available

    October 2021
  85. ZHU Y, Huang Y, Hu Y, Fang Y, et al
    Long-term Risk of Colorectal Cancer after Removal of Adenomas during Screening Colonoscopies in a Large Community-based Population in China.
    Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33835.
    PubMed     Abstract available

    August 2021
  86. ZHAO S, Chen L, Zang Y, Liu W, et al
    Endometrial cancer in lynch syndrome.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33763.
    PubMed     Abstract available

    July 2021
  87. VAN DER ZEE RP, Meijer CJLM, Cuming T, Kreuter A, et al
    Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki-67, HPV-E4, and DNA methylation markers.
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33748.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.